Fig. 6.

Dual inhibition of sialylation and fucosylation in prostate cancer cells does not promote any side effects on other glycans. Glycome analysis of PC3 prostate cancer cells treated with specific mono- or combination treatments targeting fucosylation and sialylation using a lectin panel. PC3 cells were treated with 100 μM A2FF1P, 100 μM B2FF1P, 30 μM Fucotrim I, 2 μM P-SiaFNEtoc, or with the combination therapies AE (A2FF1P + P-SiaFNEtoc), BE (B2FF1P + P-SiaFNEtoc), and F1E (Fucotrim1 + P-SiaFNEtoc). Lectin flow cytometry was performed for A) pan-specific Lectenz, B) PNA lectin, C) SNA lectin, D) MAL-II lectin, E) WGA lectin, F) AAL lectin, G) AOL lectin, H) LCA lectin, and I) L-PHA lectin. Signal intensities were compared to a DMSO only control. J) N-glycan and O-glycan mass spectrometry analysis of inhibitor and control treated PC3 cells. Monosaccharide symbols follow the SNFG (Symbol Nomenclature for Glycans) system (Varki et al. 2015).